OCT 30, 2022
In this interview with Retina Subspecialty Day co-chair Dr. Srinivas Sadda, he discussed several of the talks.
- His favorite talk was Dr. Tanya Trinh's presentation about unconscious gender bias, where she laid out the issues and problems very clearly.
- The two-year Oaks and Derby trials show a modest but clear benefit from pegcetacoplan for treatment of geographic atrophy secondary to AMD. Dr. Sadda described which patients he would offer it to first.
- Biologics will give new options for therapies, which also means decisions will have to be made and payers may dictate which agents are used and which ones physicians will have to start with.
- Dr. Sadda's takeaway point from his own talk is that there is a need for automated deep learning tools to take advantage of having these new biomarkers to identify patients at risk for dry AMD and allow for earlier assessments before they have irreversible vision loss.